AmerisourceBergen Corp. (NYSE: ABC), Valley Forge, PA, reported sales for the 2013 fiscal year ended September 30 of $88 billion, an increase of 12.7 percent compared to the same period a year ago. Profit decreased 39.7 percent to $433.7 million.
Steven H. Collis, president and CEO, said the company began a new expanded contract with Walgreen Co. during the fourth quarter. Sales for the quarter were $24.5 billion, an increase of 28.3 percent compared to the same period a year ago. Profit decreased 68.8 percent to $51 million.
The pharmaceutical distribution segment, which includes AmerisourceBergen Drug Corp. and AmerisourceBergen Specialty Group, had sales of $24.1 billion in the fourth quarter, an increase of 29 percent compared to the same period a year ago. ABDC revenues increased 34 percent, due primarily to the on-boarding of the new Walgreens branded pharmaceuticals business and increased sales to the company’s large PBM customer. ABSG revenues increased 12 percent, driven by third-party logistics and the blood products, vaccine and physician office distribution businesses.
AmerisourceBergen’s other segment, which includes AmerisourceBergen Consulting Services and World Courier, had sales of $433.6 million, an increase of 3 percent year-on-year.
